ArticleInternational journal of clinical and experimental pathology2018
The putative tumour suppressor microRNA-145, repressed by c-jun, modulates clear cell renal cell carcinoma aggressiveness by repressing ROCK1.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
- MicroRNA-145 in urologic tumors: biological roles, regulatory networks, and clinical translation.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aberrant expression of miR-145 has frequently been reported in cancer studies; however, its role in renal cell carcinoma (RCC) has not been examined in detail. Here, we showed that miR-145 was downregulated in RCC cells and tissues and associated with a poor prognostic phenotype in RCC patients. Restoration of miR-145 suppressed proliferation and invasion and induced apoptosis in clear cell RCC (ccRCC) cells. By luciferase and western blot assays we identified ROCK1 as a direct target gene for miR-145. Furthermore, a reverse correlation between miR-145 and ROCK1 expression was observed in ccRCC tissues. In addition, we revealed that miR-145 down-regulation in ccRCC cells was due to EZH2-mediated histone methylation. Altogether, these results identify a crucial tumor suppressive role of miR-145 in the progression of ccRCC and suggest that miR-145 might be an anticancer therapeutic target for ccRCC patients.
Indexed as
Identifiers
31938095PMC6957973W3026631599What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.